Joseph H. Gardner
Founder chez Aerpio Therapeutics, Inc.
Profil
Joseph H.
Gardner is the founder.
He founded Aerpio Therapeutics, Inc. in 2011, Akebia Therapeutics, Inc. in 2007, and Aerpio Pharmaceuticals, Inc. in 2007.
At Aerpio Therapeutics, Inc., he holds the title of President & Director.
At Akebia Therapeutics, Inc., he held the title of President, Chief Executive Officer & Director from 2007 to 2013.
At Aerpio Pharmaceuticals, Inc., he held the title of President, Chief Executive Officer & Director from 2019 to 2021.
Dr. Gardner also held former positions at Procter & Gamble Pharmaceuticals, Inc. as Director-Intellectual Property Management and at JDRF International as Director.
In terms of education, Dr. Gardner received his undergraduate degree from Tulane University (Louisiana) in 1977.
He obtained his doctorate degree from the University of Wisconsin in 1983.
He also received a graduate degree from Utah State University in 1980.
Postes actifs de Joseph H. Gardner
Sociétés | Poste | Début |
---|---|---|
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Founder | 01/01/2011 |
Anciens postes connus de Joseph H. Gardner
Sociétés | Poste | Fin |
---|---|---|
AERPIO PHARMACEUTICALS | Chief Executive Officer | 26/08/2021 |
AKEBIA THERAPEUTICS, INC. | Founder | 15/09/2013 |
Procter & Gamble Pharmaceuticals, Inc.
Procter & Gamble Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Procter & Gamble Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its products include Actonel, Asacol, Enablex, Didronel, Macrobid, Macrodantin, Entex, and Ziac. The firm manufactures and markets a variety of over-the-counter and oral care products such as Crest, Oral-B, Prilosec OTC, Vicks, Metamucil, Pepto-Bismol, ThermaCare, and other related products. The company was founded in 1970 and is headquartered in Cincinnati, OH. | Corporate Officer/Principal | - |
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Director/Board Member | - |
Formation de Joseph H. Gardner
Tulane University (Louisiana) | Undergraduate Degree |
University of Wisconsin | Doctorate Degree |
Utah State University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
AKEBIA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Procter & Gamble Pharmaceuticals, Inc.
Procter & Gamble Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Procter & Gamble Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its products include Actonel, Asacol, Enablex, Didronel, Macrobid, Macrodantin, Entex, and Ziac. The firm manufactures and markets a variety of over-the-counter and oral care products such as Crest, Oral-B, Prilosec OTC, Vicks, Metamucil, Pepto-Bismol, ThermaCare, and other related products. The company was founded in 1970 and is headquartered in Cincinnati, OH. | Health Technology |
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Commercial Services |
Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |